Carry out the cooperation between the medical and engineering communities and realize commercialization.
Idiopathic hypogonadotropin hypogonadism (IHH) is caused by the impaired neuron function of the congenital hypothalamus gonadotropin releasing hormone (GnRH), the dysfunction of the GnRH synthesis, secretion and function. All these result in decreased secretion of gonadotropin by pituitary gland, and then result in insufficient gonadal function, which is called IHH. It is also known as congenital hypogonadotropic hypogonadism (CHH). The clinical application of GnRH pulse therapy began in 1982 and is mainly used for the treatment of IHH. Meanwhile, the domestic GnRH pulse pump was developed and tested for clinical use. Due to technical restrictions, it cannot be used in clinical practice. At the beginning of the 21st century, the new pulse pump with micro motor technology and especially developed artificial intelligence control system has become significantly smaller in size and can be infused at required time and amount; The frequency and dose of infusion are adjustable; The pulse infusion is quick and accurate; The product is easy to operate with high safety. At present, the only similar product registered and marketed overseas is the CRONO FE micropulse infusion pump. Its drawback is that the device is not easy to hide from visibility and the portability is not good.